» Authors » P B McGlave

P B McGlave

Explore the profile of P B McGlave including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 110
Citations 1287
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Ramirez P, Wagner J, DeFor T, Blazar B, Verneris M, Miller J, et al.
Bone Marrow Transplant . 2011 Sep; 47(6):799-803. PMID: 21946383
Double umbilical cord blood transplantation (dUCBT), developed as a strategy to treat large number of patients with hematologic malignancies, frequently leads to the long-term establishment of a new hematopoietic system...
2.
Long-Boyle J, Green K, Brunstein C, Cao Q, Rogosheske J, Weisdorf D, et al.
Bone Marrow Transplant . 2010 Apr; 46(1):20-6. PMID: 20383215
Despite its common use in nonmyeloablative preparative regimens, the pharmacokinetics of fludarabine are poorly characterized in hematopoietic cell transplantation (HCT) recipients and exposure-response relationships remain undefined. The objective of this...
3.
Brunstein C, Barker J, Weisdorf D, DeFor T, McKenna D, Chong S, et al.
Bone Marrow Transplant . 2009 Jan; 43(12):935-40. PMID: 19139736
The time to neutrophil engraftment for adult patients after myeloablative double unit umbilical cord blood (UCB) transplantation is 23 days when the two units are given i.v. We hypothesized that...
4.
Carter A, Robison L, Francisco L, Smith D, Grant M, Baker K, et al.
Bone Marrow Transplant . 2006 Apr; 37(11):1023-9. PMID: 16604098
We conducted a retrospective study to describe the magnitude of compromise in reproductive function and investigate pregnancy outcomes in 619 women and partners of men treated with autologous (n=241) or...
5.
Arora M, McGlave P, Burns L, Miller J, Barke J, DeFor T, et al.
Bone Marrow Transplant . 2005 Apr; 35(12):1133-40. PMID: 15834435
We compared the results of autologous and allogeneic peripheral blood hematopoietic cell transplant (HCT) in 87 patients with multiple myeloma using myeloablative preparative regimen. Autologous transplant (n=70) led to a...
6.
Davies S, DeFor T, McGlave P, Miller J, Verfaillie C, Wagner J, et al.
Am J Med . 2001 Apr; 110(5):339-46. PMID: 11286947
Purpose: To determine if the favorable outcomes after transplantation of matched sibling donor bone marrow in patients with chronic myelogenous leukemia can be achieved using bone marrow from an HLA-A,B/DRB1-matched...
7.
Brunstein C, Hirsch B, Miller J, McGlennen R, Verfaillie C, McGlave P, et al.
Bone Marrow Transplant . 2001 Jan; 26(11):1173-7. PMID: 11149727
Autologous reconstitution is the recovery of autologous hematopoietic function after failure of an allogeneic graft to establish sustained hematopoiesis either with or without preceding donor engraftment. We reviewed 9 years...
8.
Browne P, Weisdorf D, DeFor T, MILLER W, Davies S, Filipovich A, et al.
Bone Marrow Transplant . 2000 Nov; 26(8):865-9. PMID: 11081386
Chronic graft-versus-host disease (GVHD) refractory to standard immunosuppressive therapy remains a major cause of morbidity and mortality after allogeneic bone marrow transplantation (BMT). Thalidomide may be effective in some patients...
9.
Lickliter J, McGlave P, DeFor T, Miller J, Ramsay N, Verfaillie C, et al.
Bone Marrow Transplant . 2000 Oct; 26(7):723-8. PMID: 11042652
We performed a case-control analysis of 42 patients with advanced leukemia or MDS comparing peripheral blood stem cell (PBSC) with marrow grafts (BMT) from HLA-matched sibling donors. PBSC were mobilized...
10.
McGlave P, Shu X, Wen W, Anasetti C, Nademanee A, Champlin R, et al.
Blood . 2000 Mar; 95(7):2219-25. PMID: 10733488
Over a period of 8.5 years (February 1988 to October 1996), 1423 patients with chronic myelogenous leukemia (CML) underwent unrelated donor (URD) bone marrow transplants (BMTs) facilitated by the National...